NPPA Fixes Retail Prices Of 40 Formulations

PSM News /

Mumbai, 2 June 2020:

 

NPPA has fixed retail prices of 40 formulations under Drugs Prices Control Order (DPCO)- 2013 based on its 75th authority meeting held on May 20, 2020.

 

Name of the formulations include voglibose + metformin tablet (My Vobo 0.3 M), glimepiride + metformin tablet (My GainPro SR2 Forte), omeprazole + domperidone capsule (Oldolan), pantoprazole tablet (MyPrazol), glimepiride + metformin + pioglitazone tablet (MyGainPro P2), glimepiride + metformin + piaglitazone tablet (MyGainPro P1), pantoprazole +levosulpiride capsule (MyPrazol L), pantoprazole + domperidone tablet (MyPrazol D), losartan + hydrochlorothiazide tablet (MyLosdro H), telmisartan + amlodipine tablet (MyTenslo A), atorvastatin+ ezetimibe tablet, rabeprazole + domperidone tablet (Ridzogas D), rabeprazole + domperidone capsule (Ridzogas SR D) etc.

 

The manufacturer of the mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price prescribed.

 

The retail price for a pack of the formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

 

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to state drug controller and dealers.

 

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

 

The manufacturers not complying with the ceiling price and notes specified herein above shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities (EC) Act, 1955. Pharmabiz